Delivery of CD40L by viral vectors, especially oncolytic viral vectors, could stimulate CD40 signaling and elicit strong immune responses against tumor cells and produced impressive anti-tumor effects both in pre-clinical animal models and cancer patients [54–58]. The gene discussed is CD40LG; the disease is cancer.